2024
Vitamin D’s Capacity to Increase Amphetamine-Induced Dopamine Release in Healthy Humans: A Clinical Translational [11C]-PHNO Positron Emission Tomography Study
Worhunsky P, Mignosa M, Gallezot J, Pittman B, Nabulsi N, Stryjewski A, Jalilian-Khave L, Trinko R, DiLeone R, Carson R, Malison R, Potenza M, Angarita G. Vitamin D’s Capacity to Increase Amphetamine-Induced Dopamine Release in Healthy Humans: A Clinical Translational [11C]-PHNO Positron Emission Tomography Study. Biological Psychiatry 2024 PMID: 39395473, DOI: 10.1016/j.biopsych.2024.09.028.Peer-Reviewed Original ResearchVentral striatumEffects of medicationDorsal caudateDopamine releaseDorsal putamenDopaminergic tonePlacebo-controlled within-subject studyIncreased amphetamine-induced dopamine releaseAmphetamine-induced dopamine releaseAmphetamine-stimulated dopamine releaseSubstantia nigraDysregulated dopamine functionPositron emission tomography studiesTreatment of ADHDEmission tomography studiesWithin-subject studyPost-amphetamineD2/3 receptorsDopamine functionTransdiagnostic relevanceVitamin DPhasic releaseGlobus pallidusStriatumTyrosine hydroxylaseClinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights
Honhar P, Sadabad F, Tinaz S, Gallezot J, Dias M, Naganawa M, Yang Y, Henry S, Hillmer A, Gao H, Najafzadeh S, Comley R, Nabulsi N, Huang Y, Finnema S, Carson R, Matuskey D. Clinical correlates of dopamine transporter availability in cross-sectional and longitudinal studies with [18F]FE-PE2I PET: independent validation with new insights. Brain Communications 2024, 6: fcae345. PMID: 39429243, PMCID: PMC11487911, DOI: 10.1093/braincomms/fcae345.Peer-Reviewed Original ResearchDAT availabilityMotor severitySubstantia nigraDopamine transporter availabilityClinical trials of Parkinson's diseaseParkinson's diseaseLongitudinal studyTracking longitudinal changesClinical correlatesVentral striatumTransporter availabilityNigrostriatal regionParkinson's disease patientsPutamenMotor severity scoresAssociated with increasesSubstantiaDATLongitudinal changesTremor scoreNegative associationNigraSubstantia nigra of Parkinson's disease patientsTremor severityPET biomarkersSynaptic loss and its association with symptom severity in Parkinson’s disease
Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 42. PMID: 38402233, PMCID: PMC10894197, DOI: 10.1038/s41531-024-00655-9.Peer-Reviewed Original ResearchSynaptic density lossPositron emission tomographyBinds to synaptic vesicle glycoprotein 2AAssociated with symptom severityParkinson's diseaseHigh-resolution positron emission tomographySynaptic vesicle glycoprotein 2ADuration of illnessPositron emission tomography scanBrain perfusionIllness durationSymptom severitySeverity of symptomsHC groupSubstantia nigraSynaptic densityLiving brainPD individualsClinical insightsDensity lossPD patientsEmission tomographyBrainSynaptic lossSynapse loss
2014
Dopamine D3 receptor alterations in cocaine-dependent humans imaged with [11C](+)PHNO
Matuskey D, Gallezot JD, Pittman B, Williams W, Wanyiri J, Gaiser E, Lee DE, Hannestad J, Lim K, Zheng MQ, Lin SF, Labaree D, Potenza MN, Carson RE, Malison RT, Ding YS. Dopamine D3 receptor alterations in cocaine-dependent humans imaged with [11C](+)PHNO. Drug And Alcohol Dependence 2014, 139: 100-105. PMID: 24717909, PMCID: PMC4071607, DOI: 10.1016/j.drugalcdep.2014.03.013.Peer-Reviewed Original ResearchConceptsCocaine dependenceCD subjectsIllicit substance abuseHealthy control subjectsCocaine-dependent humansGroup differencesHistory of cocaineReference tissue modelDopaminergic transmissionReceptor alterationsSubstantia nigraControl subjectsAnimal modelsReceptor availabilityEarly abstinenceCocaine useSubstance abuseBPND valuesAvailable receptorsPilot studyAmygdalaReference regionPallidumReceptorsPotential relevance
2013
Imaging Nicotine- and Amphetamine-Induced Dopamine Release in Rhesus Monkeys with [11C]PHNO vs [11C]raclopride PET
Gallezot JD, Kloczynski T, Weinzimmer D, Labaree D, Zheng MQ, Lim K, Rabiner EA, Ridler K, Pittman B, Huang Y, Carson RE, Morris ED, Cosgrove KP. Imaging Nicotine- and Amphetamine-Induced Dopamine Release in Rhesus Monkeys with [11C]PHNO vs [11C]raclopride PET. Neuropsychopharmacology 2013, 39: 866-874. PMID: 24220025, PMCID: PMC3924521, DOI: 10.1038/npp.2013.286.Peer-Reviewed Original ResearchConceptsAmphetamine-induced DA releaseD2/D3 receptorsDA releaseD3 receptorsRhesus monkeysAmphetamine-Induced Dopamine ReleaseDopamine D2/D3 receptorsHuman tobacco smokersAmphetamine-induced changesClinical neuroimaging studiesAdult rhesus monkeysPositron emission tomography (PET) imagingEmission Tomography ImagingLow-affinity receptorsNon-human primatesTobacco smokersSubstantia nigraGlobus pallidusDopamine releaseNucleus accumbensNicotineNeuroimaging studiesTomography imagingBPNDReceptors
2009
Decrease of Nicotinic Receptors in the Nigrostriatal System in Parkinson's Disease
Kas A, Bottlaender M, Gallezot JD, Vidailhet M, Villafane G, Grégoire MC, Coulon C, Valette H, Dollé F, Ribeiro MJ, Hantraye P, Remy P. Decrease of Nicotinic Receptors in the Nigrostriatal System in Parkinson's Disease. Cerebrovascular And Brain Metabolism Reviews 2009, 29: 1601-1608. PMID: 19491921, DOI: 10.1038/jcbfm.2009.74.Peer-Reviewed Original ResearchConceptsParkinson's diseasePositron emission tomographyDistribution volumeDopaminergic functionPD severityCerebral nicotinic acetylcholine receptorsStriatal dopaminergic functionNicotinic acetylcholine receptorsNAChR densityNeuroprotective actionNigrostriatal systemClinical scoresPD patientsSubstantia nigraHealthy controlsPD groupPostmortem studiesLower incidenceNicotinic receptorsPET markersPET scansPD stagesAcetylcholine receptorsEmission tomographyDisease